Bangalore Wealth Management:Indian valve rise!Hydra THV published a 30 -day research results in Europcr

Indian valve rise!Hydra THV published a 30 -day research results in Europcr

Another involved valve from India is MyVal, from Meril, India.Myval valve and Edward’s Sapien 3 are extremely similar. They have also obtained CE certification and are widely sold in Europe.Edward has repeatedly sued Meril’s patent infringement, and there have been patent disputes on various components of MyVal, including valve, balloon catheter, conveying system, and even the design of the deviceBangalore Wealth Management. Meril has also sued Edward Monopoly market.The two companies fell in love and killed each otherChennai Stock. They were tried in patent litigation in Denmark, Greece, Hungary, Italy, Poland, Portugal, Slovakia, Spain, and Turkey.But it does not prevent Myval from continuously expanding and eroding Edward’s market.

At the EuropCR 2024 conference this year, Meril announced a clinical research data (LANDMARK) about its TAVR products MyVAL and industry benchmarks (EVOLUT and Sapien 3). The results show that myval clinical effects are not inferior to Edward and Metron TAVR products.

From the recent results, it can be found that the experimental results, technical maturity, and international popularity of Indian companies’ valves are no longer inferior to international brands.In particular, Europe is the main battlefield of Indian medical companies.In fact, India’s local TAVR has not currently not been there. It is far less than that of the Indian market. However, the international popularity and overseas sales of Indian companies have surpassed India’s valve.This can also inspire domestic valve companies. Instead of rolling in the limited Indian market, it is better to earn foreigners money to go to sea.

At present, Myval has started clinical trials in India.Once obtaining a certificate, with its excellent mouth and low manufacturing costs of India, it is very likely to kill the Quartet in India.

India’s local involvement of valve surgery is about 1.6 million rubles, about 19,000 US dollars, equivalent to about 130,000 yuan.

The Indian market has been approved by 6 valves, 4 domestic and 2 imports.And there are more than ten valves in the process of obtaining a certificate.The imported Midunli and Edward did not cause much impact on the Indian market due to expensive pricesVaranasi Stock. However, after the cheaper Indian valve entered the field, can domestic brands still competeAhmedabad Wealth Management?

New Delhi Wealth Management